Long-term follow-up of 163 consecutive patients treated with isolated limb perfusion for in-transit metastases of malignant melanoma

Olofsson, Roger; Mattsson, Jan; Lindnér, Per

doi:10.3109/02656736.2013.802374

Cited by 47 publications

(45 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The main goal of TM-ILP is to achieve local control in the affected limb. The local recurrence rate in this study was 59% and comparable with local control after a first TM-ILP [11,18]. Two patients (5%) remained free of recurrence (follow-up 31 and 126 months after the last TM-ILP).…”

Section: Discussionsupporting

confidence: 66%

See 1 more Smart Citation

Repeated isolated limb perfusion in melanoma patients with recurrent in-transit metastases

Deroose

Grünhagen²,

Eggermont³

et al. 2015

Melanoma Research

View full text Add to dashboard Cite

In-transit metastases of melanoma occur in 5-8% of all melanoma patients. In case of extensive locoregional disease, Tumor necrosis factor-α and melphalan-based isolated limb perfusion (TM-ILP) had proven to yield excellent local control. Here, we report on repeat TM-ILP for locoregional recurrence after isolated limb perfusion. Between 1991 and 2013, 37 consecutive repeat TM-ILPs were analyzed in 32 different patients. Three patients underwent a third TM-ILP. During a median follow-up of 20 months after repeat TM-ILP, the overall response rate was 86%. Complete response (CR) was recorded after 24 TM-ILPs (65%). CR after first TM-ILP was a strong predictor for successful repeat TM-ILP in terms of clinical response and local recurrence. Local toxicity was mild (70% Wieberdink I-II). The local recurrence rate was 59%. Five-year overall survival was 35%. Repeat TM-ILP is a safe treatment modality in melanoma patients with recurrent in-transit metastases of melanoma. Those with a CR after first TM-ILP benefit the most from repeat TM-ILP.

show abstract

Section: Discussionsupporting

confidence: 66%

“…These rates did not differ significantly compared with those treated for the first time with TM-ILP [18]. The main goal of TM-ILP is to achieve local control in the affected limb.…”

Section: Discussionmentioning

confidence: 79%

Repeated isolated limb perfusion in melanoma patients with recurrent in-transit metastases

Deroose

Grünhagen²,

Eggermont³

et al. 2015

Melanoma Research

View full text Add to dashboard Cite

show abstract

“…(52)(53)(54)(55) The heating process can be accelerated using infrared radiation. (56) For some applications, regional heating is sufficient with invasive approaches like intraperitoneal irrigation (57) or circulating blood that is heated by exteriorized arterio-venus shunts through organs (58) or limbs (59) .…”

Section: Whole Body Heatingmentioning

confidence: 99%

Hyperthermia, Radiation and Chemotherapy: The Role of Heat in Multidisciplinary Cancer Care

Hurwitz

Stauffer

2014

Seminars in Oncology

123

104

View full text Add to dashboard Cite

“…Table summarizes the key data for each modality and presents the pooled results including the weighted ORR and meta‐analysis data. Assessed studies included: randomized controlled trials, nonrandomized phase I and II comparative and noncomparative studies, and prospective or retrospective case series (NHMRC levels II–IV evidence; Tables S2‐S9) . Only two therapies: amputation and topical imiquimod, were suitable for formal meta‐analysis ( I 2 value ≤ 40%).…”

Section: Resultsmentioning

confidence: 99%

A systematic review and meta‐analysis of locoregional treatments for in‐transit melanoma

Read

Lonne

Sparks

et al. 2019

Journal of Surgical Oncology

View full text Add to dashboard Cite

Background and Objectives In‐transit melanoma (ITM) metastases present a therapeutic challenge and management decisions can be difficult. There are multiple treatments available, with differing efficacy, and supported by different levels of evidence. The primary objective was to perform a systematic review and where suitable, a meta‐analysis of the literature reporting on the use of locoregional treatments for the management of ITM. Methods An independent review was conducted including a comprehensive search of the National Library of Medicine using PubMed, MEDLINE, Embase, and Cochrane Library databases. Key data were tabulated, synthesized and pooled to calculate relevant weighted effect sizes for each therapy using random‐effect models. The statistical heterogeneity was calculated using the Higgins' method. Results Of the initial 32 612 articles identified, 57 original articles satisfied eligibility criteria. Eight treatment modalities were identified comprising: amputation (7); hyperthermic isolated limb perfusion (15); isolated limb infusion (8); carbon dioxide laser (9); PV‐10 intralesional therapy (5); IL‐2 intralesional therapy (8); imiquimod (7); diphenylcyclopropenone (3). Only amputation and topical imiquimod were suitable for formal meta‐analysis. Conclusions All of the assessed therapies have significant selection bias. Variable levels of evidence support the ongoing use of locoregional treatments and these may significantly improve disease‐free survival.

show abstract

Long-term follow-up of 163 consecutive patients treated with isolated limb perfusion for in-transit metastases of malignant melanoma

Abstract: We found that ILP is a safe method with a high response rate for the treatment of patients with in-transit metastases of malignant melanoma.

Cited by 47 publications

References 22 publications

Repeated isolated limb perfusion in melanoma patients with recurrent in-transit metastases

Repeated isolated limb perfusion in melanoma patients with recurrent in-transit metastases

Hyperthermia, Radiation and Chemotherapy: The Role of Heat in Multidisciplinary Cancer Care

A systematic review and meta‐analysis of locoregional treatments for in‐transit melanoma

Contact Info

Product

Resources

About